Page last updated: 2024-08-22

camptothecin and dx 8951

camptothecin has been researched along with dx 8951 in 67 studies

Research

Studies (67)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	8 (11.94)	18.2507
2000's	47 (70.15)	29.6817
2010's	7 (10.45)	24.3611
2020's	5 (7.46)	2.80

Authors

Authors	Studies
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR	1
Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR	1
Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR	1
Aonuma, M; Ejima, A; Hirota, Y; Kumazawa, E; Mitsui, I; Ohsuki, S; Sato, K; Sugimori, M; Terasawa, H; Uoto, K	1
Ishii, M; Joto, N; Kuga, H; Minami, M; Mitsui, I; Tohgo, A	1
Kono, A; Kumazawa, E; Shimazoe, T; Takiguchi, S; Tohgo, A	1
Saijo, N	2
Jimbo, T; Kumazawa, E; Ochi, Y; Tohgo, A	1
Ishida, T; Mori, M; Nishio, K; Nomoto, T; Saijo, N	1
Bigg, DC; Lavergne, O	1
Clark, GM; De Jager, RL; Izbicka, E; Lawrence, RA; Rowinsky, EK; Tohgo, A; Von Hoff, DD; Weitman, SD	1
Beran, M; Giles, FJ; Jeha, S; Kantarjian, H; Smith, TL; Vey, N	1
Nakaoka, M; Oguma, T; Ohshima, Y	1
Ejima, A; Imagawa, S; Ishii, M; Iwahana, M; Minami, M; Mitsui, I; Tohgo, A	1
Coyle, J; De Jager, RL; Drengler, R; Eckhardt, SG; Geyer, CE; Hammond, LA; Johnson, TR; Rizzo, J; Rowinsky, EK; Schwartz, G; Smetzer, L; Tolcher, A; Von Hoff, DD	1
Armand, JP; Boige, V; Ducreux, M; Faivre, S; Gatineau, M; Meely, K; Mekhaldi, S; Pautier, P; Raymond, E; Rixe, O	1
Boven, E; Hoogsteen, I; Pinedo, HM; Schlüper, HM; Van Hattum, AH	1
Cheverton, P; Coyle, J; De Jager, R; Ducharme, M; Sakamoto, N; Satomi, M; Suzuki, M; Tamanoi, K	1
Bevers, M; Kavanagh, JJ; Kudelka, AP; Levenback, C; Loyer, E; Verschraegen, CF; Vincent, M; Wolf, J	1
Inukai, K; Konno, T; Nakaoka, M; Oguma, T; Yamada, M	1
Coyle, J; De Jager, R; Ducharme, MP; Dumas, P; Hoff, PM; Lassere, Y; Lee, JJ; Pazdur, R; Royce, ME	1
Inaba, A; Konno, T; Nakaoka, M; Oguma, T	1
Coyle, J; De Jager, RL; Ducharme, MP; Hollywood, E; Ilson, D; Kelsen, D; Kemeny, N; Kleban, S; O'Reilly, E; Saltz, LB; Schwartz, GK; Sharma, S	1
Nishiyama, M; Okamoto, R; Okamura, T; Park, JS; Sekikawa, T; Sparreboom, A; Takano, H; Tanimoto, K; Verweij, J; Yamamoto, W	1
Inoue, K	1
Cortes, JE; De Jager, RL; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, S; Kantarjian, HM; Thomas, DA	1
Boven, E; Erkelens, CA; Pinedo, HM; Schlüper, HM; Tohgo, A; van Hattum, AH	1
Boven, E; Hoogsteen, IJ; Kohlhagen, G; Maliepaard, M; Pinedo, HM; Pommier, Y; Scheffer, GL; Scheper, RJ; Schlüper, HM; van Hattum, AH	1
Bouvet, M; Hoffman, RM; Moossa, AR; Nassirpour, R; Sun, FX; Tohgo, A; Yagi, S	1
Bates, NP; Boven, E; Braybrooke, JP; Cheverton, PD; Dobbs, N; Pinedo, HM; Ruijter, R; Talbot, DC	1
Bailly, C; Lansiaux, A	1
Coyle, J; De Jager, RL; Ducharme, M; Figueroa, JA; Garrison, MA; Geyer, CE; Hammond, LA; Rowinsky, EK; Schwartz, G; Smetzer, L; Takimoto, CH; Tolcher, AW	1
Braybrooke, JP; Cheverton, P; Manegold, C; Mattson, K; Oyama, R; Ranson, M; Sekiguchi, M; Suzuki, M; Talbot, DC; Thatcher, N	1
Colucci, P; Cristofanilli, M; DeJager, R; Duggal, A; Esteva, FJ; Hortobagyi, GN; Rivera, E; Royce, M; Valero, V	1
Bastien, L; De Jager, R; Duggal, A; Hu, W; Kavanagh, JJ; Kudelka, AP; Loyer, E; Verschraegen, CF; Vincent, M	1
Coyle, J; DeJager, R; Hoff, PM; Pazdur, R; Rowinsky, EK; Royce, ME; Saltz, LB	1
Kumazawa, E; Ochi, Y	1
Masubuchi, N	1
Adams, M; Atkinson, R; Boven, E; Calvert, AH; Cervantes, A; Cheverton, P; Clamp, A; Ganesan, T; Jayson, GC; Lotz, J; Vasey, P	1
Atsumi, R; Masubuchi, N; May, RD	1
Atsumi, R; Iwasaki, D; Morikawa, H; Oguma, T	1
Kuga, H; Kumazawa, E; Ochi, Y; Shiose, Y	1
Alexander, J; Becker, RC; Bovill, E; Dyke, CK; Harrington, RA; Kunitada, S; Li, YF; Robertson, TL; Spencer, FA	1
Atsumi, R; Cicci, D; Gaudette, F; Gauthier-Dubois, G; Guilbaud, R; Oguma, T	1
Büchler, MW; Cheverton, P; Friess, H; Kleeff, J; Langman, S; Wanders, J; Wente, MN	1
Abou-Alfa, GK; Becerra, CR; De Jager, R; Eckhardt, SG; Feit, K; Kelsen, DP; O'Reilly, EM; Patt, YZ; Rowinsky, EK; Schwartz, GK; Sharma, S; Siegel, E	1
Ajani, JA; Baez, L; Becerra, CR; Cohn, A; De Jager, R; Feit, K; Kamida, M; Major, P; Silva, A; Takimoto, C	1
Richards, DA	1
Takimoto, CH	1
Chua, YJ; Cunningham, D	1
Abou-Alfa, GK; Ackerman, J; De Jager, RL; Eckhardt, SG; Feit, K; Harker, G; Hurwitz, H; Letourneau, R; Modiano, M; O'Reilly, EM; Tchekmedyian, NS	1
Owen, OG	1
Hashida, M; Kuga, H; Shiose, Y; Yamashita, F	1
Al Harbi, T; Al-Faris, N; Doyle, J; Gassas, A; Goia, C; Pappo, A	1
Bauer, S; Blay, JY; Christensen, TB; Daugaard, S; Hartmann, JT; Marreaud, S; Nielsen, OS; Pink, D; Reichardt, P; Schöffski, P; Van Glabbeke, M	1
Hashida, M; Kuga, H; Ochi, Y; Shiose, Y; Yamashita, F	1
Herzog, TJ; Wethington, SL; Wright, JD	1
Abe, Y; Ashida, S; Honda, T; Kasuya, Y; Masuda, T; Miyazaki, H; Morita, K; Naito, H; Nakada, T; Ogitani, Y; Yamaguchi, J; Yoshida, M	1
Li, XF; Liu, GF; Liu, L; Yu, SN; Zhang, SH	1
Agatsuma, T; Ishida, S; Ishii, C; Iwata, TN; Ogitani, Y; Wada, T	1
Doi, T; Hirotani, K; Kagari, T; Koga, Y; Koganemaru, S; Kojima, T; Kuboki, Y; Maeda, N; Matsumura, Y; Yamauchi, M; Yasunaga, M	1
Abe, M; Abe, Y; Agatsuma, T; Hashimoto, Y; Hayakawa, I; Hirotani, K; Iguchi, T; Ishizaka, T; Kagari, T; Kamai, Y; Kaneda, Y; Karibe, T; Koyama, K; Maeda, N; Morita, K; Murakami, M; Nakada, T; Nomura, T; Ogitani, Y; Shiose, Y; Ueno, S; Wakita, K; Zembutsu, A	1
Aida, T; Kai, K; Kishino, Y; Kumagai, K; Mori, K; Tsuchiya, Y	1
Agama, KK; Arakawa, Y; Bindra, RS; Choi, WS; Gayle, S; Jo, U; Jones, K; Murai, Y; Paralkar, V; Pommier, Y; Saha, LK; Sun, Y; Sundaram, RK; Van Doorn, J; Vasquez, JC; Yang, X	1
Gayle, S; Jones, K; Paradis, T; Paralkar, VM; Vasquez, J	1
Ashley, GW; Carreras, CW; Fontaine, SD; Reid, RR; Santi, DV	1

Reviews

9 review(s) available for camptothecin and dx 8951

Article	Year
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience. Chest, 1998, Volume: 113, Issue:1 Suppl Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	1998
[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan]. Bulletin du cancer, 1998, Volume: Spec No Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Macromolecular Substances; Mice; Molecular Structure; Neoplasm Proteins; Prodrugs; Structure-Activity Relationship; Topoisomerase I Inhibitors	1998
DX-8951f: summary of phase I clinical trials. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Humans	2000
Preclinical and clinical trials of topoisomerase inhibitors. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors	2000
[Drug delivery systems for cancer chemotherapy]. Nihon Geka Gakkai zasshi, 2002, Volume: 103, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Humans; Lung Neoplasms; Particle Size	2002
Chemotherapeutic gemcitabine doublets in pancreatic carcinoma. Seminars in oncology, 2005, Volume: 32, Issue:4 Suppl 6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate	2005
Chemotherapy for advanced pancreatic cancer. Best practice & research. Clinical gastroenterology, 2006, Volume: 20, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Palliative Care; Pancreatic Neoplasms; Pemetrexed; Taxoids; Topoisomerase I Inhibitors	2006
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert review of anticancer therapy, 2008, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	2008
Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis. Journal of cellular physiology, 2018, Volume: 233, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2018

Trials

18 trial(s) available for camptothecin and dx 8951

Article	Year
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia; Vomiting	2000
Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-01, Volume: 18, Issue:23 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Vomiting	2000
Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Topotecan	2000
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Thrombocytopenia	2001
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12 Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors	2001
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:7 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Stomatitis; Topoisomerase I Inhibitors	2002
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors	2003
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Time Factors	2003
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Finland; Germany; Humans; Infusions, Intravenous; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome; United Kingdom	2003
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer, 2003, Sep-01, Volume: 98, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome	2003
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Topotecan	2004
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum. Investigational new drugs, 2004, Volume: 22, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Male; Middle Aged; Rectal Neoplasms	2004
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. Gynecologic oncology, 2004, Volume: 95, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids; Topoisomerase I Inhibitors	2004
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors. Investigational new drugs, 2005, Volume: 23, Issue:4 Topics: Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Delayed-Action Preparations; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Prodrugs; Tissue Distribution; Topoisomerase I Inhibitors	2005
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. American journal of clinical oncology, 2005, Volume: 28, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Area Under Curve; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Drug Administration Schedule; Female; Gallbladder Neoplasms; Half-Life; Humans; Male; Middle Aged; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome	2005
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Investigational new drugs, 2005, Volume: 23, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Stomach Neoplasms; Treatment Outcome	2005
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-20, Volume: 24, Issue:27 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome	2006
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group. European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Leiomyosarcoma; Male; Middle Aged; Prospective Studies; Sarcoma, Synovial; Treatment Outcome	2007

Other Studies

40 other study(ies) available for camptothecin and dx 8951

Article	Year
Highly predictive and interpretable models for PAMPA permeability. Bioorganic & medicinal chemistry, 2017, 02-01, Volume: 25, Issue:3 Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine	2017
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity. Bioorganic & medicinal chemistry, 2019, 07-15, Volume: 27, Issue:14 Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility	2019
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models. Scientific reports, 2020, 11-26, Volume: 10, Issue:1 Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States	2020
A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Japanese journal of cancer research : Gann, 1995, Volume: 86, Issue:8 Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Solubility; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured; Water	1995
DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. International journal of cancer, 1997, Aug-07, Volume: 72, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Flow Cytometry; Humans; Irinotecan; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Water	1997
Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Japanese journal of cancer research : Gann, 1997, Volume: 88, Issue:8 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA Fragmentation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Splenic Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	1997
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Stomach Neoplasms; Subrenal Capsule Assay; Tumor Cells, Cultured	1998
Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f. Japanese journal of cancer research : Gann, 1998, Volume: 89, Issue:11 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Water	1998
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells. Anti-cancer drugs, 1999, Volume: 10, Issue:7 Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Dose-Response Relationship, Drug; Humans; Irinotecan; Neoplastic Stem Cells; Topotecan; Tumor Cells, Cultured	1999
The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Survival Analysis; Time Factors; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured	2000
Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection. Journal of chromatography. B, Biomedical sciences and applications, 2000, Apr-14, Volume: 740, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Drug Stability; Humans; Hydroxy Acids; Indicators and Reagents; Lactones; Solutions; Spectrometry, Fluorescence	2000
Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Anti-cancer drugs, 2000, Volume: 11, Issue:5 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Small Cell; Cisplatin; DNA Primers; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Stability; Fluorouracil; Glutathione; Glutathione S-Transferase pi; Glutathione Transferase; Humans; In Vitro Techniques; Inactivation, Metabolic; Isoenzymes; Lung Neoplasms; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors; Tubulin; Tubulin Modulators; Tumor Cells, Cultured	2000
New analogues of camptothecins. Activity and resistance. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2000
High-Performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (exatecan), in mouse plasma. Biological & pharmaceutical bulletin, 2001, Volume: 24, Issue:2 Topics: Animals; Antineoplastic Agents; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Hydroxy Acids; Lactones; Male; Mice; Mice, Inbred BALB C; Reproducibility of Results; Sensitivity and Specificity	2001
Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry. Biomedical chromatography : BMC, 2001, Volume: 15, Issue:2 Topics: Antineoplastic Agents; Atmospheric Pressure; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Sensitivity and Specificity	2001
O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Japanese journal of cancer research : Gann, 2002, Volume: 93, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glutathione; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Plasmids; RNA, Messenger; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2002
The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. Biochemical pharmacology, 2002, Oct-15, Volume: 64, Issue:8 Topics: Animals; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Division; Cisplatin; Colonic Neoplasms; Disease Models, Animal; Female; Humans; Membrane Glycoproteins; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Ovarian Neoplasms; Sulfhydryl Reagents; Tetraspanin 29; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Xenograft Model Antitumor Assays	2002
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity. British journal of cancer, 2002, Sep-09, Volume: 87, Issue:6 Topics: Acridines; Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Isoquinolines; Membrane Glycoproteins; Mice; Mice, Nude; Mutation; Neoplasm Proteins; Neoplasms, Experimental; Ovarian Neoplasms; Tetrahydroisoquinolines; Tetraspanin 29; Tetrazolium Salts; Thiazoles; Topoisomerase I Inhibitors; Tumor Cells, Cultured	2002
Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer research, 2003, Jan-01, Volume: 63, Issue:1 Topics: Animals; Camptothecin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured	2003
[A symphony for the camptothecins]. Bulletin du cancer, 2003, Volume: 90, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan	2003
DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models. Cancer science, 2004, Volume: 95, Issue:2 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Male; Mice; Neoplasms, Experimental	2004
Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice. Die Pharmazie, 2004, Volume: 59, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Drug Carriers; Fibrosarcoma; Half-Life; Injections, Intravenous; Mice; Mice, Inbred BALB C; Neoplasm Transplantation	2004
A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-01, Volume: 10, Issue:19 Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Camptothecin; Colony-Forming Units Assay; Dogs; Granulocyte Precursor Cells; Granulocytes; Humans; Inhibitory Concentration 50; Irinotecan; Macrophages; Maximum Tolerated Dose; Mice; Models, Biological	2004
Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in tumor tissue by high performance liquid chromatography/atmospheric pressure chemical ionization tan Biomedical chromatography : BMC, 2005, Volume: 19, Issue:1 Topics: Animals; Atmospheric Pressure; Camptothecin; Chromatography, High Pressure Liquid; Drug Carriers; Drug Stability; Fibrosarcoma; Freezing; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Reproducibility of Results; Sensitivity and Specificity	2005
A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951. Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:4 Topics: Animals; Antineoplastic Agents; Ascites; Camptothecin; Chromatography, High Pressure Liquid; Endocytosis; Fibrosarcoma; Fluorescence; Injections, Intraperitoneal; Lysosomes; Macrophages; Mice; Microscopy, Confocal; Neoplasm Transplantation; Tumor Cells, Cultured	2005
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist. Thrombosis and haemostasis, 2004, Volume: 92, Issue:6 Topics: Anticoagulants; Blood Coagulation Tests; Calcium Chloride; Camptothecin; Drug Synergism; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular-Weight; Humans; Sensitivity and Specificity	2004
Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in human plasma by HPLC and LC/MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2005, Apr-25, Volume: 818, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Stability; Humans; Mass Spectrometry; Reproducibility of Results; Sensitivity and Specificity; Thermolysin	2005
Are there any better camptothecins than the ones we have? Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Irinotecan; Pancreatic Neoplasms; Research; Topoisomerase I Inhibitors	2003
Exatecan and gemcitabine: no better than gemcitabine only. The Lancet. Oncology, 2006, Volume: 7, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate	2006
Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f. Journal of pharmaceutical and biomedical analysis, 2007, Mar-12, Volume: 43, Issue:4 Topics: Acids; Camptothecin; Chromatography, High Pressure Liquid; Drug Carriers; Drug Stability; Enzyme Inhibitors; Hydrolysis; Magnetic Resonance Spectroscopy; Molecular Structure; Prodrugs; Reproducibility of Results	2007
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatric blood & cancer, 2007, Volume: 49, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Infection Control; Kaplan-Meier Estimate; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Postoperative Care; Retrospective Studies; Risk; Salvage Therapy; Sarcoma, Ewing; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vincristine	2007
Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors. Biological & pharmaceutical bulletin, 2007, Volume: 30, Issue:12 Topics: Animals; Antineoplastic Agents; Camptothecin; Cathepsins; Cell Line, Tumor; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Humans; Hydrolysis; Liver; Mice; Neoplasm Transplantation; Neoplasms; Prodrugs; Tissue Distribution; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays	2007
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorganic & medicinal chemistry letters, 2016, Mar-15, Volume: 26, Issue:6 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Injections, Intraventricular; Mammary Neoplasms, Experimental; Mice; Molecular Conformation; Structure-Activity Relationship; Trastuzumab	2016
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Molecular cancer therapeutics, 2018, Volume: 17, Issue:7 Topics: Animals; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Breast Neoplasms; Camptothecin; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Mice; Programmed Cell Death 1 Receptor; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays	2018
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer. Molecular cancer therapeutics, 2019, Volume: 18, Issue:11 Topics: Animals; Antibodies, Monoclonal, Humanized; Broadly Neutralizing Antibodies; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Immunoconjugates; Mice; Receptor, ErbB-3; Up-Regulation; Xenograft Model Antitumor Assays	2019
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-01, Volume: 25, Issue:23 Topics: Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Camptothecin; Cell Proliferation; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Macaca fascicularis; Male; Mice; Mice, Inbred NOD; Mice, Nude; Neoplasms; Rats; Receptor, ErbB-3; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2019
Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer science, 2020, Volume: 111, Issue:12 Topics: Animals; Camptothecin; Cathepsin B; Drug Administration Schedule; Female; Immunoconjugates; Lung; Lung Diseases, Interstitial; Macaca fascicularis; Male; Receptor, ErbB-2; Time Factors; Trastuzumab	2020
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Molecular cancer therapeutics, 2022, 07-05, Volume: 21, Issue:7 Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Camptothecin; DNA; DNA Topoisomerases, Type I; Humans; Mice; Neoplasms; Nuclear Proteins; Protein Kinase Inhibitors; Topoisomerase I Inhibitors	2022
Antigen-independent tumor targeting by CBX-12 (alphalex Immunotherapy, 2022, Volume: 14, Issue:18 Topics: Animals; Camptothecin; Cell Line, Tumor; Immunity; Immunotherapy; Neoplasms; Tumor Microenvironment	2022
A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors. Cancer research communications, 2023, Volume: 3, Issue:5 Topics: Animals; Antineoplastic Agents; Camptothecin; DNA Damage; Humans; Mice; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols	2023